Antihypertensive medications comparison
Pro Research Analysisby 
Searched over 200M research papers
Comparative Efficacy of Antihypertensive Drug Classes for Cardiovascular Disease Prevention
Large-scale analyses show that angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB) are the most effective antihypertensive drug classes for reducing major cardiovascular events compared to placebo. Diuretics also show a beneficial trend, while beta-blockers and renin inhibitors do not demonstrate significant reductions in cardiovascular risk. Among these, ARB and CCB have acceptability profiles similar to placebo, meaning patients are less likely to discontinue these medications due to side effects. In contrast, ACEi, beta-blockers, and alpha-blockers are associated with higher rates of treatment discontinuation. This suggests that ARB and CCB may be the most suitable first-line agents for many patients, though some inconsistencies in the data warrant cautious interpretation Brunström2023Wei2020.
Effectiveness of Antihypertensive Drug Combinations
Combination therapy is often recommended for hypertension management, especially in patients who do not achieve control with a single agent. Among drug combinations, those pairing renin-angiotensin system inhibitors (such as ACEi or ARB) with CCBs are the most effective in preventing major cardiovascular events. Combinations of thiazide and potassium-sparing diuretics also show good efficacy. However, combinations of renin-angiotensin system inhibitors with diuretics appear less effective. In terms of acceptability, combinations including ARB tend to be better tolerated, while those with ACEi may lead to more discontinuations, though differences are not always statistically significant Brunström2023Cavero-Redondo2023.
Real-World Use of Monotherapy vs. Combination Therapy
Despite guideline recommendations favoring combination therapy, real-world data indicate that most patients start with monotherapy. Over time, the use of two or more antihypertensive drugs increases, but monotherapy remains the most common approach, even after several years of treatment. Single-pill combinations are preferred when combinations are used, but three-drug combinations are rare. These patterns are consistent across different age groups, sexes, and clinical backgrounds .
Impact on Arterial Stiffness
For patients with hypertension and increased arterial stiffness, thiazide diuretics, ACEi, ARB, and combinations such as ACEi/ARB, ACEi/CCB, and ARB/CCB are particularly effective in reducing arterial stiffness, as measured by pulse wave velocity and augmentation index. This suggests these agents may offer additional vascular benefits beyond blood pressure reduction .
Gender Differences in Antihypertensive Medication Use and Effectiveness
Women are slightly more likely than men to use antihypertensive medications, but the effectiveness of these drugs in controlling blood pressure is similar between genders. Blood pressure control is less likely in younger adults, Black and Hispanic populations, obese individuals, and those using CCBs .
Safety and Cancer Risk
There is no evidence that commonly used antihypertensive drugs—including ACEi, ARB, beta-blockers, diuretics, and CCBs—increase the risk of cancer compared to placebo or untreated controls .
Timing of Antihypertensive Medication Dosing
Recent large trials show no significant difference in cardiovascular outcomes between morning and evening dosing of antihypertensive medications. Patients can take their medications at a time that is most convenient for them, as long as they maintain consistent 24-hour blood pressure control. Current guidelines do not recommend routine bedtime dosing Mackenzie2022Stergiou2022.
Conclusion
ACEi, ARB, and CCB are the most effective antihypertensive drug classes for preventing major cardiovascular events, with ARB and CCB also being better tolerated. Combination therapy, especially RAS inhibitors with CCBs, offers additional benefits, but real-world use still favors monotherapy. There are no significant safety concerns regarding cancer risk, and the timing of medication dosing can be flexible. These findings support individualized treatment choices based on efficacy, tolerability, and patient preference.
Sources and full results
Most relevant research papers on this topic